期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 62, 期 4, 页码 453-456出版社
BLACKWELL PUBLISHING
DOI: 10.1111/j.1365-2125.2006.02639.x
关键词
azathioprine; breastfeeding; pharmacogenetics; pharmacokinetics
Aims To determine infant exposure to 6-thioguanine and 6-methylmercaptopurine nucleotides (6-TGN and 6-MMPN, respectively) during maternal use of azathioprine in breastfeeding. Methods Mother-infant pairs provided blood for determination of 6-TGN and 6-MMPN concentrations, and TPMT genotype. Results Four women taking azathioprine 1.2-2.1 mg kg(-1) day(-1) and their infants were studied. All had the wild-type TPMT genotype. Maternal 6-TGN and 6-MMPN concentrations ranged from 234 to 291 and 284 to 1178 pmol per 8 x 10(8) red blood cells, respectively, and were consistent with those associated with improved therapeutic outcomes. Neither 6-TGN nor 6-MMPN was detected in any of the infants, despite a sensitive assay. Conclusions The data suggest that azathioprine may be 'safe' during breastfeeding in patients with the wild-type TPMT genotype (similar to 90% of caucasian patients) taking 'normal' doses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据